Vaccine Info

Shingrix Shingles Vaccine

Shingrix Shingles Vaccine Description

Shingrix is an adjuvanted recombinant zoster vaccine, consisting of the varicella-zoster virus glycoprotein E antigen and the AS01B adjuvant system, a proprietary adjuvant containing QS-21 and MPL with liposomes. 

Shingrix Shingles Vaccine Indication

Shingrix is a vaccine for the prevention of shingles (herpes zoster) in adults 50 years and older.

Shingrix is not used to prevent primary varicella infection (chickenpox).

Shingrix Shingles Vaccine Dosage

Shingrix is a suspension for intramuscular injection only. It is supplied in 2 vials that must be combined prior to administration. Two doses are necessary to provide strong protection, up to 90%, the first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.

The CDC has stated: If more than 6 months have elapsed since the 1st Shingrix dose, administer the 2nd dose as soon as possible. Do not restart the Shingrix vaccine series.

Shingrix Shingles Vaccine Updates

  • April 29, 2020 - GSK announced Shingrix sales grew 81% AER, 79% CER to £647 million, primarily driven by continued strong uptake in the US. Germany and Canada also contributed to growth.
  • February 27, 2020 - The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
  • February 2020 - Aggregate health and economic burden of herpes zoster in the United States.
  • November 29, 2019 - This study suggests that exogenous boosting provides some protection from the risk of herpes zoster, but not complete immunity, as assumed by previous cost-effectiveness estimates of varicella immunization.
  • October 23, 2019 - Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling.
  • May 22, 2019 - China’s National Medical Product Administration (NMPA) announced the ‘conditional approval’ for Shingrix.
  • July 9, 2019 - GSK Herpes Zoster Vaccine Shingrix reduced the incidence of herpes zoster in autologous stem cell transplant recipients.
  • September 22, 2018 - The Journal of Infectious Diseases, Volume 218.
  • January 26, 2018 - Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.

Shingrix Shingles Vaccine Clinical Trials 

NCT00434577, NCT00492648, NCT00802464, NCT00920218, NCT01086449, NCT01165177, NCT01165203, NCT01165229, NCT01295320, NCT01751165, NCT01777321, NCT01827839, NCT01954251 and NCT02075515

Updated
04/30/2020 - 16:45